Anika Therapeutics Swings to Q2 Profit on 16% Revenue Jump, Margin Expansion
ANIK has more than doubled off its 52-week low of $7.87.
Summary
Anika Therapeutics reported Q2 2026 revenue of $32.6M (+16% YoY) and swung to a $3.3M profit from continuing operations, with gross margin expanding to 65%. Cash declined to $38.4M, but a new $50M credit facility provides additional liquidity.
Key Events · Earnings and Guidance · ANIK
-
Q2 Revenue Up 16%
Revenue reached $32.6 million, driven by a 14% increase in OEM Channel sales (primarily J&J MedTech) and a 17% increase in Commercial Channel sales, including higher Integrity and international OA pain management product sales.
-
Swung to Profitability
Net income from continuing operations was $3.3 million, or $0.24 per diluted share, compared to a loss of $4.6 million in Q2 2025. The improvement was driven by higher sales volume and gross margin expansion.
-
Gross Margin Expanded to 65%
Gross margin improved to 65% from 51% a year ago, reflecting higher manufacturing production, improved sales mix, and lower costs.
-
Cash Declined to $38.4M
Cash and cash equivalents fell to $38.4 million from $57.5 million at year-end 2025, primarily due to $9.5 million in share repurchases and an $11.4 million inventory build.
Analysis · ANIK · Industrial Applications And Services
A sharp turnaround defined Anika Therapeutics' Q2 2026, as net income from continuing operations reached $3.3 million, reversing a $4.6 million loss a year ago. Revenue climbed 16% to $32.6 million, fueled by stronger OEM and Commercial Channel sales, while gross margin surged to 65% from 51% thanks to improved manufacturing efficiency and mix. Liquidity got a boost from a subsequent $50 million credit facility extension to 2031. On the other side of the ledger, cash reserves dropped to $38.4 million from $57.5 million at year-end, partly reflecting $9.5 million in share repurchases and a working capital build. The results underscore significant operational progress following recent restructuring and divestitures, though cash burn and heavy reliance on a single customer—J&J MedTech at 53% of revenue—remain key risks.
At the time of this filing, ANIK was trading at $16.49 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $215.2M. The 52-week trading range was $7.87 to $17.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.